Literature DB >> 22735187

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Nicole Exner1, Anne Kathrin Lutz, Christian Haass, Konstanze F Winklhofer.   

Abstract

Neurons are critically dependent on mitochondrial integrity based on specific morphological, biochemical, and physiological features. They are characterized by high rates of metabolic activity and need to respond promptly to activity-dependent fluctuations in bioenergetic demand. The dimensions and polarity of neurons require efficient transport of mitochondria to hot spots of energy consumption, such as presynaptic and postsynaptic sites. Moreover, the postmitotic state of neurons in combination with their exposure to intrinsic and extrinsic neuronal stress factors call for a high fidelity of mitochondrial quality control systems. Consequently, it is not surprising that mitochondrial alterations can promote neuronal dysfunction and degeneration. In particular, mitochondrial dysfunction has long been implicated in the etiopathogenesis of Parkinson's disease (PD), based on the observation that mitochondrial toxins can cause parkinsonism in humans and animal models. Substantial progress towards understanding the role of mitochondria in the disease process has been made by the identification and characterization of genes causing familial variants of PD. Studies on the function and dysfunction of these genes revealed that various aspects of mitochondrial biology appear to be affected in PD, comprising mitochondrial biogenesis, bioenergetics, dynamics, transport, and quality control.

Entities:  

Mesh:

Year:  2012        PMID: 22735187      PMCID: PMC3400019          DOI: 10.1038/emboj.2012.170

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  383 in total

1.  Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.

Authors:  Sathya R Sriram; Xiaojie Li; Han Seok Ko; Kenny K K Chung; Esther Wong; Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2005-07-27       Impact factor: 6.150

2.  Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy.

Authors:  Vinay Choubey; Dzhamilja Safiulina; Annika Vaarmann; Michal Cagalinec; Przemyslaw Wareski; Malle Kuum; Alexander Zharkovsky; Allen Kaasik
Journal:  J Biol Chem       Date:  2011-01-20       Impact factor: 5.157

3.  Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease.

Authors:  Hongxia Wang; Pingping Song; Lei Du; Weili Tian; Wen Yue; Min Liu; Dengwen Li; Bin Wang; Yushan Zhu; Cheng Cao; Jun Zhou; Quan Chen
Journal:  J Biol Chem       Date:  2011-02-03       Impact factor: 5.157

4.  Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

Authors:  João Paulo L Daher; Olga Pletnikova; Saskia Biskup; Alessandra Musso; Sandra Gellhaar; Dagmar Galter; Juan C Troncoso; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  Hum Mol Genet       Date:  2012-02-21       Impact factor: 6.150

5.  PINK1 controls mitochondrial localization of Parkin through direct phosphorylation.

Authors:  Yongsung Kim; Jeehye Park; Sunhong Kim; Saera Song; Seok-Kyu Kwon; Sang-Hee Lee; Tohru Kitada; Jin-Man Kim; Jongkyeong Chung
Journal:  Biochem Biophys Res Commun       Date:  2008-10-26       Impact factor: 3.575

6.  Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Li Rebekah Feng; Kathleen Maguire-Zeiss; Gw Rebeck; Hilal A Lashuel; Charbel Eh Moussa
Journal:  Mol Neurodegener       Date:  2010-11-04       Impact factor: 14.195

7.  Enhanced vulnerability of PARK6 patient skin fibroblasts to apoptosis induced by proteasomal stress.

Authors:  M Klinkenberg; N Thurow; S Gispert; F Ricciardi; F Eich; J H M Prehn; G Auburger; D Kögel
Journal:  Neuroscience       Date:  2010-01-04       Impact factor: 3.590

8.  Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways.

Authors:  Takafumi Hasegawa; Angela Treis; Nadja Patenge; Fabienne C Fiesel; Wolfdieter Springer; Philipp J Kahle
Journal:  J Neurochem       Date:  2008-02-04       Impact factor: 5.372

Review 9.  α-Synuclein and dopamine at the crossroads of Parkinson's disease.

Authors:  Lara Lourenço Venda; Stephanie J Cragg; Vladimir L Buchman; Richard Wade-Martins
Journal:  Trends Neurosci       Date:  2010-10-18       Impact factor: 13.837

10.  Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity.

Authors:  Francisco A Perez; Wendy R Curtis; Richard D Palmiter
Journal:  BMC Neurosci       Date:  2005-12-24       Impact factor: 3.288

View more
  210 in total

1.  PGC-1α/ERRα-Sirt3 Pathway Regulates DAergic Neuronal Death by Directly Deacetylating SOD2 and ATP Synthase β.

Authors:  Xuefei Zhang; Xiaoqing Ren; Qi Zhang; Zheyi Li; Shuaipeng Ma; Jintao Bao; Zeyang Li; Xue Bai; Liangjun Zheng; Zhong Zhang; Shujiang Shang; Chen Zhang; Chuangui Wang; Liu Cao; Qingsong Wang; Jianguo Ji
Journal:  Antioxid Redox Signal       Date:  2015-11-19       Impact factor: 8.401

2.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

3.  Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation.

Authors:  Masahiro Iguchi; Yuki Kujuro; Kei Okatsu; Fumika Koyano; Hidetaka Kosako; Mayumi Kimura; Norihiro Suzuki; Shinichiro Uchiyama; Keiji Tanaka; Noriyuki Matsuda
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

4.  Upregulation of sestrin-2 expression via P53 protects against 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity.

Authors:  Daixing Zhou; Chengye Zhan; Qiang Zhong; Shusheng Li
Journal:  J Mol Neurosci       Date:  2013-11       Impact factor: 3.444

5.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

6.  Impaired mitochondrial dynamics underlie axonal defects in hereditary spastic paraplegias.

Authors:  Kyle Denton; Yongchao Mou; Chong-Chong Xu; Dhruvi Shah; Jaerak Chang; Craig Blackstone; Xue-Jun Li
Journal:  Hum Mol Genet       Date:  2018-07-15       Impact factor: 6.150

7.  Tauroursodeoxycholic Acid Protects Against Mitochondrial Dysfunction and Cell Death via Mitophagy in Human Neuroblastoma Cells.

Authors:  Inês Fonseca; Gisela Gordino; Sara Moreira; Maria João Nunes; Carla Azevedo; Maria João Gama; Elsa Rodrigues; Cecília Maria Pereira Rodrigues; Margarida Castro-Caldas
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

8.  Choline dehydrogenase interacts with SQSTM1/p62 to recruit LC3 and stimulate mitophagy.

Authors:  Sungwoo Park; Seon-Guk Choi; Seung-Min Yoo; Jin H Son; Yong-Keun Jung
Journal:  Autophagy       Date:  2014-10-30       Impact factor: 16.016

9.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

Authors:  J A Morales-García; C Susín; S Alonso-Gil; D I Pérez; V Palomo; C Pérez; S Conde; A Santos; C Gil; A Martínez; A Pérez-Castillo
Journal:  ACS Chem Neurosci       Date:  2012-12-05       Impact factor: 4.418

Review 10.  Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases.

Authors:  Silvia Lima Costa; Victor Diogenes Amaral Silva; Cleide Dos Santos Souza; Cleonice Creusa Santos; Irmgard Paris; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2016-03-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.